PPARG and idiopathic pulmonary fibrosis: Encouraging results using PPARG agonists might be used as a starting point to carry out new investigations that lead to the development of highly effective drugs that potentiate the control of fibrosis and metabolic imbalance in those patients who require it, for example DM-IPF individuals.